Plozasiran (Redemplo) for Familial Chylomicronemia Syndrome
Abstract
Plozasiran (Redemplo – Arrowhead), an apolipoprotein C-III (apoC-III)-directed small interfering ribonucleic acid (siRNA), has been approved by the FDA to reduce triglyceride levels in adults with familial chylomicronemia syndrome (FCS). It is the second drug to be approved in the US for this indication; the apoC-III-directed antisense oligonucleotide olezarsen (Tryngolza) was approved in 2024.
Fields of Study & Subjects
Lipid metabolism and disorders
Biochemical Acid Research Studies
Ubiquitin and proteasome pathways
Publication details
- Journal / source
- The medical letter on drugs and therapeutics/The medical letter
- Publisher
- The Medical Letter, Inc.
- Volume
- 68
- Issue
- 1752
- Pages
- 68–62
- Publication date
- 13 April 2026
- Language
- EN